Live
- 17 missing after safari boat sinks in Egypt's Marsa Alam
- Cyberabad Police Arrest Two for ₹48 Crore Fraud in Pre-Launch Property Offers Scam
- Utpanna Ekadashi 2024: Date, Rituals, Significance, and Mantras
- Hyderabad Achieves 26% Reduction in PM10 Levels in 2023-24, Improving Air Quality
- Tired And Stressed As A Parent? Try These Easy Life Hacks
- Supreme Court issues notice on PIL seeking directions to integrate legal education, self-defence training into school curriculum
- Oneplus 13 Launch: OnePlus Vows Snapdragon 8 Elite and Hasselblad Cameras
- Bengal school jobs case: Arpita Mukherjee granted bail; new HC Bench to look into Partha Chatterjee's plea
- Working to provide social security for gig and platform workers: Govt
- Bangladesh records 11 dengue deaths, toll rises to 459
BA.5 Omicron subvariant 4 times more vaccine-resistant: Study
BA.5 Omicron subvariant 4 times more vaccine-resistant: Study (Photo/IANS)
The BA.5 Omicron subvariant, now the dominant coronavirus strain in the US, is four times more resistant to Covid-19 vaccines, according to a new study published in Nature.
Los Angeles: The BA.5 Omicron subvariant, now the dominant coronavirus strain in the US, is four times more resistant to Covid-19 vaccines, according to a new study published in Nature.
The study found the variant is four times more resistant to messenger RNA vaccines than earlier strains of Omicron, which include Pfizer and Moderna Covid-19 vaccines, Xinhua news agency reported.
The strain is "hypercontagious" and is contributing to increases in hospitalisations and ICU admissions, said the Mayo Clinic in a report on Thursday.
The BA.5 strain represented 65 per cent of Covid-19 cases in the country in the week ending July 9, according to the latest data from the US Centers of Disease Control and Prevention.
Unvaccinated people have about a five times higher chance of contracting the virus than those who are vaccinated and boosted, while chances of hospitalisation are 7.5 times higher, and chances of death are 14 to 15 times higher, said Gregory Poland, Head of the Mayo Clinic's Vaccine Research Group.
